Sign In
Buy TMDX
$76.51
+0.380 (+0.499%)
At Close: Jul 31, 2026
4 Top Stocks Long-Term Investors Should Buy in March
03:55am, Sunday, 08'th Mar 2026
These four tickers aren't hype stocks; they're the plumbing in solid industries. Axon Enterprise has switching costs; Vertiv is embedded in AI infrastructure; TransMedics controls a life-critical logi
Medical Stock Nears Buy Point Amid Liver Transplant Demand Surge
01:57pm, Thursday, 05'th Mar 2026
Medical stock TransMedics is in a cup-with-handle base with a buy point of 151.85.
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
12:30pm, Saturday, 28'th Feb 2026
TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.
ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
TMDX Stock Rises as Q4 Earnings & Revenues Beat Estimates
12:51pm, Wednesday, 25'th Feb 2026
TransMedics posts 200% EPS surge and 32% revenue growth in Q4, tops estimates and guides for up to 25% sales growth in 2026.
TransMedics Q4 Profit Jumps, Shares Rise
10:17am, Wednesday, 25'th Feb 2026
TransMedics (TMDX) shares rose 6.69% in pre-market trading after the company reported fourth-quarter 2025 results. Revenue for the quarter reached $160.8 millio
Breakfast News: Why Axon Enterprise Is Soaring 15%
07:30am, Wednesday, 25'th Feb 2026
Axon climbs after forecast beats, MercadoLibre e-commerce volumes soar, and more
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
02:07am, Wednesday, 25'th Feb 2026
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
TransMedics (TMDX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
09:00pm, Tuesday, 24'th Feb 2026
While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics co
TransMedics (TMDX) Beats Q4 Earnings and Revenue Estimates
08:31pm, Tuesday, 24'th Feb 2026
TransMedics (TMDX) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.19 per share a year ago.
TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Tuesday, 24'th Feb 2026
ANDOVER, Mass., Feb. 24, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
Ahead of TransMedics (TMDX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
10:16am, Monday, 23'rd Feb 2026
Besides Wall Street's top-and-bottom-line estimates for TransMedics (TMDX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
GSA Capital Partners LLP Makes New Investment in TransMedics Group, Inc. $TMDX
05:52am, Monday, 23'rd Feb 2026
GSA Capital Partners LLP purchased a new stake in TransMedics Group, Inc. (NASDAQ: TMDX) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Friday, 20'th Feb 2026
ANDOVER, Mass., Feb. 20, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
TransMedics to Present at Upcoming March Investor Conferences
04:05pm, Tuesday, 17'th Feb 2026
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s
